Frontiers in neurology · 2025
Hekun decoction versus Femoston for women with amnestic mild cognitive impairment in early menopause: a randomized, three-arm, double-blind clinical trial.
СтатьяНазвание и аннотация: Перевод пока не подготовлен
Обработка статьи · этапы, ошибки и управление
Загрузка состояния…
Ошибки и ограничения
История · было → стало
Состояние обновляется каждые 5 секунд, пока блок открыт. Процент показывается только там, где известен объём работы. Пауза останавливает продолжение этапа; текущий запрос к источнику может завершиться.
Zhai Ziqi, Lin Guangyao, Chen Siru, Liu Huicong, Yuan Rui, Gao Xianwei, Ni Xiaorong, Shen Mingjie, Fan Haiying, Wang Wenjun, Zhao Yan, Wu Yan, Gu Chao, Cong Chao, Xiao Shan, Zhang Yue, Zhao Jingchang, Xu Jiayao, Wang Ye, Chen Jie, Chen Yishuang, Zong Yan, Tang Qianjue, Li Shengnan, Zhang Zhijie, Xu Lianwei
Аннотация
BACKGROUND: Amnestic mild cognitive impairment (aMCI), a prodromal stage of Alzheimer's disease (AD), carries a high risk of progression to dementia. However, few clinical trials have focused on interventions to delay this progression. Hekun Decoction, an herbal-based oral medicine, has shown potential in improving memory loss during early menopause. Here we performed a randomized controlled trial to evaluate the efficacy and safety of Hekun Decoction in women with aMCI.
METHODS: This prospective, randomized, three-arm, double-blind clinical trial enrolled women aged 40-60 years with aMCI during early menopause. Participants were randomized to Hekun Decoction, Femoston, or placebo for 24 weeks. The primary outcome was the change in the Montreal Cognitive Assessment (MoCA) score at 0 and 24 weeks. The secondary outcomes included the Menopause Rating Scale (MRS), Modified Kupperman Index (KI), and Insomnia Severity Index (ISI), along with adverse events.
RESULTS: Between October 2021 and February 2024, a total of 292 patients were randomized to Hekun Decoction (n = 98), Femoston (n = 98), and placebo (n = 96). After 24 weeks, both Hekun Decoction (MD = 3.18, 95% CI [2.44-3.92]) and Femoston (MD = 3.67, 95% CI [2.93-4.42]) were more effective than placebo in improving MoCA scores. Meanwhile, better outcomes were observed in the Hekun Decoction group and Femoston group compared with the placebo group for MRS (MD = -5.87, 95% CI [-7.02, -4.71], and MD = -6.01, 95% CI [-7.02, -5.01]), KI (MD = -6.74, 95% CI [-8.16, -5.33], and MD = -6.93, 95% CI [-8.27, -5.59]), and ISI (MD = -6.53, 95% CI [-7.66, -5.39], and MD = -6.51, 95% CI [-7.58, -5.43]). As for the adverse events, no cases of abdominal distension, pain, breast pain, or abnormal uterine bleeding were observed in the Hekun Decoction group.
CONCLUSION: In women with aMCI during early menopause, Hekun Decoction demonstrated non-inferior efficacy to Femoston in improving cognitive function over 24 weeks, with a favorable safety profile. Notably, women in the Hekun Decoction group showed fewer adverse events compared with Femoston. However, further trials with longer follow-up periods are needed to confirm the efficacy of Hekun Decoction in women with aMCI.
CLINICAL TRIAL REGISTRATION: http://chictr.org.cn, ChiCTR2000036772.
METHODS: This prospective, randomized, three-arm, double-blind clinical trial enrolled women aged 40-60 years with aMCI during early menopause. Participants were randomized to Hekun Decoction, Femoston, or placebo for 24 weeks. The primary outcome was the change in the Montreal Cognitive Assessment (MoCA) score at 0 and 24 weeks. The secondary outcomes included the Menopause Rating Scale (MRS), Modified Kupperman Index (KI), and Insomnia Severity Index (ISI), along with adverse events.
RESULTS: Between October 2021 and February 2024, a total of 292 patients were randomized to Hekun Decoction (n = 98), Femoston (n = 98), and placebo (n = 96). After 24 weeks, both Hekun Decoction (MD = 3.18, 95% CI [2.44-3.92]) and Femoston (MD = 3.67, 95% CI [2.93-4.42]) were more effective than placebo in improving MoCA scores. Meanwhile, better outcomes were observed in the Hekun Decoction group and Femoston group compared with the placebo group for MRS (MD = -5.87, 95% CI [-7.02, -4.71], and MD = -6.01, 95% CI [-7.02, -5.01]), KI (MD = -6.74, 95% CI [-8.16, -5.33], and MD = -6.93, 95% CI [-8.27, -5.59]), and ISI (MD = -6.53, 95% CI [-7.66, -5.39], and MD = -6.51, 95% CI [-7.58, -5.43]). As for the adverse events, no cases of abdominal distension, pain, breast pain, or abnormal uterine bleeding were observed in the Hekun Decoction group.
CONCLUSION: In women with aMCI during early menopause, Hekun Decoction demonstrated non-inferior efficacy to Femoston in improving cognitive function over 24 weeks, with a favorable safety profile. Notably, women in the Hekun Decoction group showed fewer adverse events compared with Femoston. However, further trials with longer follow-up periods are needed to confirm the efficacy of Hekun Decoction in women with aMCI.
CLINICAL TRIAL REGISTRATION: http://chictr.org.cn, ChiCTR2000036772.